First human tests begin for new RSV shot
NCT ID NCT07106918
Summary
This is an early-stage study to test the safety and body processing of a new vaccine injection, called SIBP-A16, designed to protect against Respiratory Syncytial Virus (RSV). It will involve 140 healthy adults who will receive different doses or a placebo. The main goal is to see how well the vaccine is tolerated and to measure its levels in the blood over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wuhan Jinyintan Hospital
RECRUITINGWuhan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.